2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Food and Drug Administration Perspective

Nakissa Sadrieh

Nakissa Sadrieh

Associate Director for Research Policy and Implementation
Food and Drug Administration (FDA)

Dr. Sadrieh obtained her doctorate in Toxicology in 1993 from Rutgers University in New Jersey. Following a postdoctoral fellowship in the Laboratory of Chemical Carcinogenesis at the National Cancer Institute, Dr. Sadrieh joined the Food and Drug Administration in 1996 as a pharmacology and toxicology reviewer. In 1998, Dr. Sadrieh became the supervisory pharmacologist in the Division of Medical Imaging and Radiopharmaceutical Drug Products, Center for Drug Evaluation and Research (CDER). Dr. Sadrieh has been directly involved in the review and approval of many drug products and subsequently she has expertise in the preclinical studies needed to support the safety of new drug applications.

In 2002, Dr. Sadrieh joined CDER’s Office of Pharmaceutical Science, as the Associate Director for Research Policy and Implementation. Dr. Sadrieh’s work currently focuses on scientific research that will directly impact regulatory decisions. As a scientific advisor to the Office of Pharmaceutical Science, Dr. Sadrieh is also directly involved in assessing the impact of new technologies on drug development. Nanotechnology, having been identified as an opportunity under the FDA’s Critical Path Initiative, is one area which is expected to impact regulatory submissions in the future. As such, Dr. Sadrieh is the chair of the CDER Nanotechnology Working Group, as well as the CDER representative on several other nanotechnology interest groups within the Agency and the National Institutes of Health.

Speaking in the special symposium on Nanotechnology for Cancer Prevention, Diagnosis and Treatment.

View Confimed Speakers

Back to Conferences & Symposia


Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.